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Abstract 
The ability of synthetic peptides based on the amino-terminus of HIV-1 glycoprotein 41 000 (gp41) to fuse human erythrocytes was 
investigated. Previous site-directed mutagenesis studies have shown an important role for the N-terminal gp41 domain in HIV-fusion, in 
which replacement of hydrophobic amino acids with polar residues inhibits viral infection and syncytia formation. Here, a synthetic 
peptide (FP; 23 amino acid residues 519-541) corresponding to the N-terminus of HIV-1 gp41, and also a FP analog (FP526L/R) with 
Arg replacing Leu-526, were prepared with solid phase techniques. The lipid mixing and leakage of resealed ghosts triggered by these 
peptides were examined with fluorescence quenching techniques. Peptide-induced aggregation of human erythrocytes was studied using 
Coulter counter sizing and scanning electron microscopy (SEM). Using resealed erythrocyte ghosts at physiologic pH, FP induces rapid 
lipid mixing between red cell membranes at doses previously shown to hemolyze intact cells. FP also causes leakage from resealed 
ghosts, and promotes the formation of multicelled aggregates with whole erythrocytes. Contrarily, similar FP526L/R concentrations did 
not induce red cell lysis, lipid mixing, leakage or aggregation. Since the fusogenic potency of FP and FP526L/R parallels earlier gp41 
mutagenesis studies showing that substitution of Arg for Leu-526 blocks fusion activity, these data suggest hat the N-terminal gp41 
domain in intact HIV participates in fusion. 
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1. Introduction 
Recent evidence supports the hypotheses that the 
amino-terminal peptide (approx. 23 amino acid residues 
Abbreviations: PBS, phosphate-buffered saline; DMSO, dimethyl sul- 
foxide; HIV-1, Human Immunodeficiency Virus, Type-l; gp41, glyco- 
protein 41 000 of HIV-1; gpl20, glycoprotein 120000 of HIV-1; FP, HIV 
amino-terminal peptide 519-541 of gp41; FP526L/R, a FP analog in 
which Leu-526 is replaced by Arg; HIV-L, C-terminal peptide 828-855 
of gp41; SEM, scanning electron microscopy; RIs, octadecyl rhodamine 
B chloride; ANTS, aminonapthalene-l,3,6-trisulfonic acid; DPX, p- 
xylene-bis-pyridinium bromide; VSV, vesicular stomatitis virus; RBC, 
red blood cells; SUV, small unilamellar vesicles; LUV, large unilamellar 
vesicles; POPG, l-palmitoyl-2-oleoyl phosphatidylglycerol; POPC, 1-pal- 
mitoyl-2-oleoyl phosphatidylcholine; DOPC, dioleoylphosphatidyl- 
choline; DOPE, dioleoylphosphatidylethanolamine; K D, dissociation con- 
stant. 
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519-541 [1]) of glycoprotein 41 000 (gp41) plays critical 
roles in the fusion and cytopathic processes underlying 
HIV-1 infection of target cells [2]. With myxoviruses and 
paramyxoviruses, the fusion site on the viral envelope 
protein is a conserved hydrophobic amino acid sequence at 
the amino terminus of the F~ protein [3]. Gallaher [4] and 
Gonzalez-Scarano et al. [5] each noted extensive homolo- 
gies of these sequences with those of the N-terminus of 
gp41, and suggested that the N-terminal gp41 peptide is 
similarly involved in the fusion of the HIV envelope with 
host cells. According to a recent model [6,7], the viral 
envelope gp41 might act as a 'bridge,' fusing the target 
cell surface bilayer through the N-terminal sequence of 
gp41 with the HIV lipid bilayer [8,9]. Indeed, Koenig et al. 
[10] suggested that HIV infection of cells occurs only if 
the amino-terminal peptide interacts with the target cell 
membrane, perhaps by destabilizing the lipid bilayer. Ex- 
perimental support for these hypotheses comes from site- 
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directed mutagenesis studies showing that substitution of 
hydrophobic amino acids with polar residues in the N- 
terminal peptide lowered the infectivity of HIV and its 
ability to promote syncytium formation [11-14]. The N- 
terminal gp41 peptide might also directly kill target cells 
[4], thereby contributing to the decline of CD4- lympho- 
cytes that is a clinical hallmark of AIDS. Consistent with 
this view is the finding that a mutation affecting the 
amino-terminal sequence of HIV-1 gp41 produced a much 
less cytopathic virus [15]. 
Although the use of site-specific mutated HIV-1 is a 
powerful tool for investigating the functional role(s) of 
viral envelope pitopes, further studies with complemen- 
tary techniques are needed before unequivocally assigning 
fusogenic and cytolytic activities to the N-terminal domain 
of gp41. In particular, Larsen et al. [16] noted that control 
experiments were not done in the above studies to show 
that site-specific mutations do not significantly perturb the 
overall gp41 structure. Furthermore, site-specific mutations 
of either the V3 region of gpl20 [14] or gp41 regions 
outside the N-terminal domain [14,17,18] inhibit postbind- 
ing fusion activities; this suggests that envelope protein 
regions other than the N-terminus of gp41 also contribute 
to the fusion process in the intact virus. 
An alternative xperimental pproach that focusses ex- 
clusively on the membrane actions of the N-terminal do- 
main of HIV-1 gp41 involves the use of synthetically-pre- 
pared peptides. For example, addition of synthetic peptides 
(i.e., 23-residue sequence 519-541 [19,20] or 16-residue 
sequence 519-534 [21]) to model liposomes induced 
lipid-mixing. Possibly related to this fusogenic activity is 
the finding with light scattering that the 23-residue se- 
quence 519-541 mediated liposome aggregation [19,20]. 
Further, the 23-residue peptide 519-541 [ 19,20] and 16-re- 
sidue peptide 519-534 [22] from HIV-1 gp41 each in- 
duced leakage of lipid vesicles. Of particular interest is the 
finding that the 23-residue peptide 519-541 induced mix- 
ing of aqueous lipid vesicle contents [20]. However, before 
these findings with liposomes can be legitimately extrapo- 
lated to HIV infection processes, further studies examining 
the biomembrane actions of the N-terminal gp41 peptide 
are required using human cells. 
In the present paper, the respective abilities of the 
synthetic N-terminal peptide of HIV-1 gp41 (FP; 23 
residues 519-541) and a site-substituted FP (FP526L/R; 
Arg replacing Leu-526) to fuse and lyse human red cell 
membranes are investigated. Previously, we have shown 
that FP lysed both intact human erythrocytes and CD4 +- 
lymphocytes [23]. In further physical-biochemical experi- 
ments on human red cells, we reported that the N-terminal 
HIV-I gp41 peptide may achieve these lytic effects by 
forming peptide aggregates in the red cell membrane [6]. 
The control peptide FP526L/R was chosen because a 
prior mutagenic study indicated that replacement of Leu- 
526 with Arg completely blocked syncytium formation, 
using CD4 + HeLa cells transfected with HIV env glyco- 
protein expression vectors [12]. Synthetic FP, but not 
FP526L/R, agglutinated red cells;, and also triggered 
lipid-mixing and leakage of resealed erythrocyte ghosts. 
These data indicate that addition of synthetic peptides to 
red cells may provide a model system for understanding 
FP-membrane interactions underly!ng HIV fusion pro- 
cesses. 
2. Materials and methods 
2.1. Materials 
Bee-venom melittin was from Sigma Chemical (St. 
Louis, MO) and was used without further purification. 
Octadecyl rhodamine B chloride (/~ 18), aminonapthalene- 
1,3,6-trisulfonic acid (ANTS) and tile quencher p-xylene- 
bis-pyridinium bromide (DPX) ~x'ere from Molecular 
Probes (Eugene, OR). Triton X-100, CaC12, MOPS, L- 
histidine, DMSO, EDTA, NaCI and bovine serum albumin 
were from Sigma Chemical (St. Louis, MO). 
The 23-amino acid N-terminal sequence of gp41 (FP; 
NH 2-Ala-Val-Gly-Ile-Gly-Ala-Leu-Phe-Leu-Gly-Phe-Leu- 
Gly-Ala-Ala-Gly-Ser-Thr-Met-Gly-Ala-Arg-Ser-CONH 2) 
of the HIV-I strain LAVIa, and also a site-substituted FP 
analog (FP526L/R; NH2-Ala-Val-Gly-Ile-Gly-Ala-Leu- 
Phe-Arg-Gly-Phe-Leu-Gly-Ala-Ala-Gly-Ser-Thr-Met-Gly- 
Ala-Arg-Ser-CONH2), were synthe.sized and purified as 
described earlier [23]. FP encompasses amino acid residues 
519-541 of HIV-1 gp41 [1]. The expected molecular 
masses of FP and FP526L/R were obtained by fast-atom 
bombardment mass spectrometry and electrospray mass 
spectrometry (UCLA Center for Molecular and Medical 
Sciences Mass Spectrometry). Quantitative amino acid 
compositions for the peptides were determined at the 
UCLA Protein Microsequencing Facility. 
2.2. Preparation of human red blood cells (RBC) 
Human red blood cells (RBC) were prepared using 
outdated units from the local blood bank [23]. All units 
tested negative for antibodies to H1V-I, and hepatitis B 
and D. Red cells were washed three times in 0.85% NaCI0 
and packed cells from the last wash were suspended in 
isotonic (phosphate-buffered saline (PBS)) buffer, consist- 
ing of 120 mM NaCI-2.7 mM KCI-10 mM Na2HPO 4 (pH 
7.4). 
2.3. Hemolysis assays of human red blood cells 
For testing of peptide-induced hemolysis, small aliquots 
(< 10 /xl) of concentrated FP, FP526L/R or melittin in 
100% DMSO were added to 0.5 ml of the isotonic PBS 
buffer to yield the desired peptide concentration. For 
Ca2+-induced hemolysis, small aliquots (_< 25 /zl) of a 
concentrated calcium stock buffer (i.e., 200 mM CaC12 in 
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isotonic PBS) were added to 0.5 ml of isotonic PBS buffer 
and cells to yield the desired Ca 2+ concentration. Aliquots 
(10 /~1) of the packed, washed cells were then added, and 
after 30 min at 37 ° C, the suspension was centrifuged at 
approx. 5000 X g for 1.5 min and the supernatant analyzed 
spectrophotometrically for hemoglobin at 543 nm [7,24]. 
Percent lysis was calculated, using a reference of the 
average of three tubes in which 10/xl of packed cells were 
incubated in 0.5 ml of distilled water for the duration of 
the experiment. Control experiments indicate that the high- 
est concentration of carrier DMSO (i.e., 2.6%) did not 
increase hemolysis. 
2.4. Preparation of resealed human red blood cell ghosts 
Lysed and resealed red cell ghosts were prepared ac- 
cording to the method of Sze and Solomon [25], with 
several modifications. Packed human red blood cells were 
washed three times in the PBS buffer with centrifugation 
at 2500 × g for 10 min (5000 rpm with a JA-20 rotor in a 
Beckman Model J2-21 centrifuge). The cells were then 
allowed to hemolyze for 30 min in 8 vol. of 5 mM 
sodium-phosphate, pH 7.4. The ghosts were pelleted by 
centrifugation at 22 000 × g for 20 min (approx. 15 000 
rpm with the JA-20 rotor). The supernatant was removed 
with a tap aspirator. The pellet was washed three more 
times with the 5 mM sodium-phosphate, pH 7.4 buffer, 
and suspended in a minimum volume (approx. 0,5 ml) of 
this buffer. The creamy white-pink ghosts were stored at 
4 ° C. Protein assays were performed using the Bio-Rad 
protein assay reagent (Richmond, CA) and bovine serum 
albumin as standard. 
Sealed ghosts were prepared by resuspending the lysed 
cells in 4-5 vol. of resealing buffer (120 mM KCI/30 mM 
NaC1/10 mM sodium phosphate, pH 7.4) containing 0.75 
mM sucrose. The mixture was incubated on ice for 15 min, 
and the ghosts were subsequently resealed at 37°C in the 
presence of 1 mM Mg 2+ for 45 min. Nonentrapped su- 
crose was removed by repeated centrifugation at 15000 
rpm for 20 rain each time. The final pellet, sucrose-loaded 
resealed ghosts, was suspended in the appropriate incuba- 
tion buffer. 
For leakage xperiments, the above protocol for prepar- 
ing resealed ghosts was modified to include fluorescent 
dye and fluorescence quencher during the resealing step 
(see below). 
2.5. Lipid-mixing (fusion) assay 
Lipid-mixing between red cell membranes was quanti- 
tated from the relief of fluorescence self-quenching of the 
membrane-incorporated fluorescent probe, octadecyl rho- 
damine B chloride (RIB). Fusion of R18-1abeled red blood 
cell ghosts with unlabeled ghosts reduces the membrane 
surface-density of the fluorophore, thereby producing an 
increase in fluorescence intensity [26]. 
For lipid-mixing experiments, the resealed ghosts were 
divided into two equal portions: one aliquot was stored on 
ice, while the other had R~8 added and was then incubated 
for l h at a final concentration of 1 mol R18/50 mol of red 
cell lipid under vortexing at room temperature. The la- 
beled, resealed ghosts was incubated in the dark for one 
hour at room temperature. Unincorporated Rj8 was re- 
moved by gel filtration on a Sephadex G-75 column 
(incubation buffer: 120 mM KC1/30 mM NaCl/10 mM 
Na2HPO4/0.1 mM EDTA), and the unlabeled, resealed 
ghosts were diluted to the same volume as the labeled, 
resealed ghosts collected from the column. 
Fluorescence intensities were recorded using a Perkin- 
Elmer 650-40 fluorescence spectrophotometer at 37 °C. 
For fusion measurements, zero fluorescence (F  0) was taken 
as the emission intensity at 590 nm (560 nm, excitation 
wavelength) of the labeled and unlabeled resealed ghosts 
(1:1) before the fusion agent is added, and 100% fluores- 
cence (F~00) is the corresponding intensity after the incu- 
bation medium is made 1% Triton X-100. E~ represents 
the fluorescence intensity, measured for a 1:1 mixture of 
labeled and unlabeled, resealed ghosts on addition of the 
putative fusion agent for the indicated time. Accordingly, 
the percent fusion may be defined as 
%Fusion= 100× [ (F~-Fo) / (F ,  oo-Fo)  ] (1) 
2.6. Leakage from resealed ghosts 
Leakage was measured with a fluorescence assay of 
resealed red blood cell ghosts containing both the water- 
soluble fluorescent marker ANTS and the quencher DPX. 
Upon membrane leakage with addition of a putative lytic 
agent, ANTS and DPX are released to the buffer medium. 
This effectively dilutes the quencher concentration, thereby 
increasing the fluorescence intensity of ANTS [27]. 
For leakage experiments, ANTS and DPX were incor- 
porated into the ghosts during the resealing step (see 
above). The resealed ghosts initially contain both ANTS 
(12.5 mM) and DPX (45 mM). Non-encapsulated 
ANTS/DPX was removed by centrifugation at22 000 × g 
(approx. 15000 rpm), 8°C for 20 rain. The pellet was 
suspended in 1 ml of running buffer (100 mM NaC1/2 
mM MOPS/2 mM L-histidine/1 mM EDTA; pH 7.4), for 
each 1 ml of lysed ghosts. This ghost solution (30 ~l) was 
mixed with the leakage agents and running buffer to a total 
volume of 1.5 ml. Fluorescence intensity of this 1.5 ml 
mixture was measured at 37 ° C at 767 nm, with an excita- 
tion wavelength at 384 rim. The initial fluorescence inten- 
sity for ghosts resealed with ANTS (12.5 rim) and DPX 
(45 mM) is zero; an increase in the fluorescence intensity 
recorded for these resealed ghosts is proportional to the 
degree of membrane leakage. Leakage results are pre- 
sented as Delta (Emission Intensity) at 767 nm, which is 
equal to the intensity recorded with a putative lytic agent 
subtracted by the corresponding intensity recorded with 
only the carrier solvent. 
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2.7. Coulter counter sizing of human e~throcytes 
The aggregation state of human red blood cells was 
assessed with Coulter counter sizing. Aliquots (10 /~1) of 
washed, packed red blood cells were incubated in 0.5 ml 
PBS with the indicated agent at 37°C for 30 min. Agents 
were added as described above for hemolysis assays. At 
the end of the incubation an aliquot of the mixture was 
diluted 1:50000 in isotonic PBS in a 20 ml disposable 
blood vial (Baxter Diagnostics, Irwine, CA). Particle num- 
bers in each of 16 size ranges were determined with a 
Coulter Counter-Model ZBI (Coulter Electronics, Hileah, 
FL), equipped with a stirrer. The total particle volume (V T) 
was calculated as the summation, over each of the 16 
channels, of the number (N c) of particles in each channel 
multiplied by the maximum particle volume (VMc) in each 
channel. % Total volume in each channel is then defined 
as: 
%Total Volume = l O0 × [(XvX V,w, ) ] / VT ] (2) 
2.8. Scanning Electron Microscopy (SEM) qf human er3,- 
throcvtes 
Samples were prepared for Scanning Electron Mi- 
croscopy (SEM) by the method of Birch et al. [28]. Red 
cells were taken from the hemolysis assay and fixed in 
2.5% glutaraldehyde for 1 h at room temperature. The 
fixed cells were placed on poly-k-lysine coated cover slips. 
After a 1 hr treatment with 2% osmium tetroxide, the 
sample was washed and dehydrated by 5 stepwise in- 
creases (at least 15 rain each) in aqueous ethylene glycol 
from 20 to 95%. Two further changes of 60% and 95% 
cellosolve in ethylene glycol and three of absolute cello- 
solve prepared the sample for critical point drying. Critical 
point drying was conducted in a 1250J critical point dryer 
from Pelco (Redding, CA). The Scanning Electron Micro- 
scope was an Amray 1000A (Bedford, MA). 
3. Results 
3.1. FP- and FP526L / R-induced fusion (lipid-mixing) of 
resealed human erythroc:vte ghosts 
Fluorescence measurements were carried out to assess 
the lipid-mixing effects of the amino-terminal peptide of 
gp41 (FP) on resealed erythrocyte ghosts. These assays 
rely on the fact that the fluorochrome RiB is heavily 
self-quenched when inserted in a membrane lipid bilayer at 
high fluorochrome/lipid (approx. l: 100). In the absence of 
lipid mixing, the dye only very slowly transfers from the 
bilayers of the labeled resealed ghosts to those of the 
unlabeled resealed ghosts. When lipid-mixing fusion oc- 
curs, the dye is rapidly diluted throughout the system and 
relief of self-quenching results in an increase in fluores- 
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Fig. 1. Time dependence of lipid mixing indtced by the amino terminal 
peptide of HIV-I gp41 (FP), a FP analog (FP526L/R) in which Arg is 
substituted for Leu-526, melittin or calcium using resealed human ery- 
throcyte ghosts at 37 ° C. Percent fusion is measured by the increase in 
fluorescence of the lipid-soluble probe, octadecyl rhodamine B chloride 
(Ris), due to relief of self-quenching upon fusion of labeled and unla- 
beled resealed ghosts (see Section 2). Complete (100%) fusion is taken as 
the maximal fluorescence resulting from treatment with 1% Triton X- 
I00. Rl~-Iabeled (200 p~l) resealed ghosts and unlabeled (200 /,tl) 
resealed ghosts were incubated with the agent for the indicated times at 
37°C in the incubation buffer (pH 7.4; 120 mM KCI/30 mM NaCI/IO 
mM Na2HPO4/O.l mM EDTA). The total volume was 1.5 ml. The 
agents tested were: FP (30 /.~M: O-O) ,  FP526L/R (34 ~M: ~-@), 
melittin (5 p,M; A - - ) ,  Ca ~+ (2 mM; B -B)  and DMSO (2.6%: E3-1~). 
FP, FP526L/R and melittin were each added to the incubation mixture 
from a DMSO (100%) stock solution, yielding the above peptide concen- 
tration and 2.6% DMSO. Excitation and emis,,;ion wavelengths were 560 
and 590 nm, respectively. Results are means cf duplicate determinations, 
and are representative of three independent experiments. 
cence. In initial time-course studies at 37 ° C, R~8-1abeled 
and -unlabeled resealed ghosts were incubated with 30 
/zM FP for various times (Fig. 1). Earlier experiments 
showed that 30 /zM FP-induced approx. 40% lysis of 
human red blood cells [23]. Maximum lipid-mixing oc- 
curred in approx. 7 rain with 30 #M FP, and this plateau 
was maintained for at least another 18 min (Fig. 1). 
Control experiments in Fig. 1 indicated that the highest 
concentration of carrier solvent (2.6% DMSO) did not 
promote lipid mixing; the 'zero' time lipid mixing was 
identical with or without 2.6% DMSO. 
For comparative purposes, the site-substituted analog of 
FP (FP526L/R) and two hemolytic agents (melittin and 2 
mM CaCI 2) were tested for their effects on lipid mixing 
between resealed erythrocyte ghosts. Fig. l shows that 
FP526L/R, at a concentration (34 /zM) slightly higher 
that used for FP, does not induce lipid-mixing; in parallel 
hemolysis experiments (data not shown), we found that 34 
/,aM FP526L/R produced less than 5% lysis of intact 
erythrocytes when incubated for 30 rain. Melittin, at a 5 
/zM peptide dosage that achieves 100% hemolysis [23], 
also did not promote lipid-mixing between resealed ghosts 
for the duration (24 min) of the experiment (Fig. 1). On 
the other hand, addition of 2 mM CaCI 2 induced lipid- 
mixing similar to that of 30 /zM FP, with maximal ipid- 
mixing occurring at approximately 15 min. The ability of 2 
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Fig. 2. Dose-dependent effects of the amino terminal peptide of HIV-I 
gp41 (FP) on the lipid-mixing of resealed human erythrocyte ghosts at 
37 ° C. The 'zero' point reflects the lipid-mixing noted with the carrier 
concentration f DMSO (2.6%). Ris-labeled (200/xl) resealed ghosts and 
unlabeled (200 /xl) resealed ghosts were incubated with the agent for 20 
min at 37 ° C in the isotonic buffer of Fig. 1. % Fusion is defined from 
Eqn. 1. Results are means of duplicate determinations, and are representa- 
tive of three independent experiments. 
mM CaCl 2 to induce lipid-mixing noted in Fig. 1 is 
consistent with previous fusion studies by Hoekstra et al. 
[29], which indicated this CaC12 concentration also pro- 
motes contents mixing of resealed ghosts. In separate 
experiments, we found that incubation of 2 mM CaC12 
with intact red cells produced approx. 25% hemolysis (data 
not shown). 
Since FP-induced lipid-mixing is maximal at 20 min in 
Fig. 1, this incubation time was used in the dose-response 
lipid-mixing curve for the peptide. Fig. 2 shows that FP 
induces a dose-dependent lipid-mixing of human red blood 
cells, with 24% lipid-mixing occurring at 30 /xM. It is of 
interest hat a similar dose-response curve was obtained 
previously for FP-induced hemolysis of human red blood 
cells [23]. 
3.2. FP- and FP526L / R-induced leakage from resealed 
human erythrocyte ghosts 
The ability of FP and FP526L/R to cause leakage of 
internal contents of resealed ghosts was examined with a 
fluorescent assay developed by Ellens et al. [27]. Here, 
ghosts were resealed with the fluorochrome ANTS and the 
quencher DPX, and leakage of ANTS and DPX into the 
medium is monitored by the fluorescence increase of 
unquenched ANTS. Fig. 3 shows that 15 /xM FP induces 
rapid leakage of the resealed ghosts, attaining the plateau 
within approx. 1 min after peptide addition. Comparable 
time-courses for leakage were noted for resealed ghosts 
incubated with 30 and 45/xM FP, with the following order 
for the maximal release of ANTS and DPX: 15 /xM 
FP < 30 /xM FP < 45 /xM FP (Fig. 3). Contrarily, experi- 
ments with 34/xM FP526L/R indicated no leakage when 
the site-substituted FP analog was added to resealed ghosts 
(Fig. 3). Although the FP concentrations that induce leak- 
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Fig, 3. Time dependence of leakage from resealed human erythrocyte 
ghosts induced by the amino terminal peptide of HIV-1 gp41 (FP) and the 
FP analog (FP526L/R) at 37 ° C. The Delta (Emission Intensity) is equal 
to the fluorescence intensity at 767 nm recorded with a putative lytic 
agent subtracted by the corresponding intensity recorded with only the 
carrier solvent (_< 2.6% DMSO). Delta (Emission Intensity) is propor- 
tional to the release of ANTS and DPX from the resealed ghosts. 
Resealed ghosts (30 /xl) containing 12.5 mM ANTS and 45 mM DPX 
were incubated with either FP526L/R (34 p~M; ~)  or the following /xM 
concentrations of FP: 15 (rT); 30 (A); and 45 (0) .  Results are means of 
duplicate determinations, and are representative of three independent 
experiments. 
age of resealed ghosts are similar to those for lipid-mixing 
(Figs. 1 and 2) and hemolysis [7,23], it should be noted 
that maximal leakage of resealed ghosts occurs much 
faster than either maximal ipid-mixing of resealed ghosts 
(approx. 7 min; Fig. 1) or maximal hemolysis of intact red 
cells (approx. 30 min; see Mobley et al. [23]). 
It is of interest o contrast FP-induced leakage of re- 
sealed ghosts with that caused by either melittin or CaCI 2. 
The time-courses for peptide-induced leakage in Fig. 4 
indicate that either 1 /~M or 2 /xM melittin does not 
400 , , , , , , , , , , , , , , 
100 ~ c ~ @ o 
V / 50> 
o - = ~ ~ - ~-~:  ~ 
.511~ I I I L I I ~ J , , I 
0 20 40 60 80 100 120  140 160 180 
T ime (seconds)  
Fig. 4. Time dependence of leakage from resealed human erythrocyte 
ghosts induced by bee-venom melittin at 37 ° C. The Delta (Emission 
Intensity) is equal to the fluorescence intensity at 767 nm recorded with a 
putative lytic agent subtracted by the corresponding intensity recorded 
with only the carrier solvent ( _% 2.6% DMSO). Delta (Emission Intensity) 
is proportional to the release of ANTS and DPX from the resealed ghosts. 
Resealed ghosts (30 /xl) containing 12.5 mM ANTS and 45 mM DPX 
were incubated with the following /xM concentrations of melittin: 1 ( A ); 
2 (• ) ;  5 (O); and 10 (• ) .  Results are means of duplicate determinations, 
and are representative of three independent experiments. 
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Fig. 5. Time dependence of leakage from resealed human erythrocyte 
ghosts induced by CaCI 2 at 37 ° C. The Delta (Emission Intensity) is 
equal to the fluorescence intensity at 767 nm recorded with a putative 
lyric agent subtracted by the corresponding intensity recorded with only 
the running buffer (see Section 2). Delta (Emission Intensity) is propor- 
tional to the release of ANTS and DPX from the resealed ghosts. 
Resealed ghosts (30 /zl) containing 12.5 mM ANTS and 45 mM DPX 
were incubated with the lollowing mM concentrations of CaC12:5 ([]); 
and 10 (0) .  Results are means of duplicate determinations, and are 
representative of three independent experiments. 
trigger significant release of contents from resealed ghosts. 
However, 5 /xM and 10 /xM melittin each produce rapid 
leakage of resealed ghosts, reaching their respective 
plateaus in 20 s (Fig. 4). Accordingly, the maximal leakage 
induced by FP (Fig. 3) or that triggered by 5 or 10 ~zM 
melittin (Fig. 4) proceed rapidly, each being completed 
within 1 min. It should also be noted that the maximal 
leakage of resealed ghosts induced by 5 or 10/zM melittin 
occurs much faster than maximal hemolysis of red cells 
(i.e., approx. 30 rain; see Mobley et al. [23]). Further, 
resealed ghosts appear to be much more resistant to melit- 
tin-induced lysis than whole red cells: 2 /~M melittin lyses 
100% of red blood cells, but has no impact on leakage of 
resealed ghosts (Fig. 4; Mobley et al. [23]). These findings 
suggest hat the mechanisms underlying FP- (or melittin-) 
induced hemolysis and leakage from resealed ghosts are 
different. A further indication that hemolysis and leakage 
of resealed ghosts reflect distinct phenomena are the find- 
ings that CaCI 2, at 5 mM and 10 mM doses that hemolyze 
red blood cells, had no effect on tl~e leakage of contents 
from resealed ghosts (Fig. 5). 
3.3. FP- and FP526L / R-induced ~tggregation f human 
red blood cells 
Since the above results showed that N-terminal HIV-1 
gp41 peptide mediates both fusogenic and cytolytic activ- 
ity with resealed erythrocyte ghosL,;, FP and FP526L/R 
were also tested for aggregation of human red cells. Coul- 
ter counter experiments were conducted on washed, packed 
red blood cells incubated in the isotonic PBS buffer with 
FP, FP526L/R, melittin and Ca 2+ for 30 min (Fig. 6). 
Counts were made for particles in channels ranging in 
maximum particle volume (/~3) from 2 to 4,224. A plot of 
the % (Total Volume) versus the maximum particle vol- 
ume is shown in Fig. 6, where % (Total Volume) is the 
percent fraction of the red cell particle volume in a given 
channel to the total volume of the particles in all channels 
(see Section 2). For 30 /zM FP and DMSO (2.6%), this 
plot is nearly symmetrical with the largest % (Total Vol- 
ume) value occurring with a maximum particle volume of 
528 /~3. Control experiments with e.ither PBS or DMSO 
(2.6%) indicated much smaller particle sizes for red blood 
cells. Specifically, the 66 /x 3 channel has the largest % 
(Total Volume) for red cells treated with either PBS or 
DMSO. The simplest interpretation f these data is that FP 
50 ~ r 50 
40 ! 40 
%Total 3o 3o %Total 
20 Volume 
Volume 2o 0 
10 
52s "~.<.~j .  ~ DMSO 
2111 CONTROL 
Max. particle volume (p3)  
Fig. 6. Coulter counter sizing of erythrocytes treated with the amino terminal peptide of HIV-I gp41 (FP), the FP analog (FP526L/R), Ca 2+, or melittin. 
Erythrocytes were tested for aggregation by incubating 10 p~l of packed red blood cells, diluted to 0.5 ml in PBS buffer, with th,~ following agents at 37 ° C 
for 30 min: 34 /xM FP and DMSO (2.6%) (cross-hatch bars); 2 mM CaCI 2 (dotted bars); 44/~M FP526L/R (narrow diagonal bars) and DMSO (2.6%); 
1.5 p,M melittin and DMSO (2.6%) (broad diagonal bars); and 2.6% DMSO (vertical bars). The control was run by adding 10 /zl of PBS buffer (white 
bars). At the end of the incubation, an aliquot of the mixture was diluted 1:50000 in isotonic phosphate-buffered saline. The number of particles in each of 
the 12 size ranges (i.e., maximum particle volume /z 3, x axis) shown was then determined with a Coulter counter. No particles were found in the four 
channels with the largest maximum particle volumes (e.g., 8448, 16 900, 33 798 and 67 000 /x3), and were omitted from this pbt. Percent (Total Volume) 
for the particles in each channel (z axis) is calculated as in Section 2. Results are means of duplicate determinations, and are representative of three 
independent experiments. 
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induces variable aggregations of erythrocytes. If it is as- 
sumed, as a first approximation, that the volume of an 
individual red cell is not substantially altered by FP incu- 
bation, then the mean number of single red cells in the 
aggregates of the 528 /z 3 channel is equal to 8 (i.e., = 528 
/z 3 (FP-treated)/66 /z3 (DMSO or PBS control)). Consis- 
tent with the interpretation that FP triggers aggregation of 
red cells is the finding that FP-treatment decreases the 
number (N) of particles by approx. 5-fold (i.e., 333 334 
(PBS control) to 65 839 (FP-incubated), where N is sam- 
pled from the standard assay with 10 /zl of packed red 
cells). The other fusogenic agent, 2 mM CaCI 2, induces a 
more modest volume increase in the erythrocyte particles; 
here, the channel with the largest % (Total Volume) 
increases from 66 to 132 /z 3 (Fig. 6). Contrarily, neither 
melittin (1.5 /xM) nor FP526L /R  (44 ~M)  and DMSO 
(2.6%) altered the particle sizes of human erythrocytes 
(Fig. 6), in agreement with these peptides not being fuso- 
genic (Fig. 1). 
Scanning electron microscopy (SEM) studies on FP- 
treated human erythrocytes confirmed that this peptide 
facilitated aggregation of red cells (Fig. 7). Control experi- 
ments on red cells treated with DMSO (2.6%) showed 
separate cells that principally share the normal discoid 
shape characteristic of erythrocytes, with occasional 
echinocyte projections (Fig. 7A,C). Incubation with the 
amino-terminal HIV-1 gp41 peptide exerts profound ef- 
fects on red cell morphology. Fig. 7B shows only multicell 
aggregates, in agreement with the above Coulter counter 
sizing results. At higher magnification, Fig. 7D indicates 
that the individual cells in the aggregates are distorted and 
elongated. Although these morphological perturbations may 
be a consequence of both hemolysis and membrane fusion, 
the absence of severely disrupted membranes in Fig. 7B,D 
Fig. 7. Scanning Electron Microscopy (SEM) of human red blood cells treated with the amino-terminal peptide of HIV-I gp41 (FP). (A) Control red cells 
suspended in isotonic PBS and incubated for 30 min with DMSO (2.6%). The white bar at the top is equal to 2 /xm; (B) Red cells suspended in isotonic 
PBS and incubated for 30 min with 34/xM FP and DMSO (2.6%). The white bar at the top is equal to 2 /zm; (C) Control red cells suspended in isotonic 
PBS and incubated for 30 min with DMSO (2.6%). The white bar at the top is equal to 0.8 /xm; (D) Red cells suspended in isotonic PBS and incubated for 
30 min with 34 /zM FP and DMSO (2.6%). The white bar at the top is equal to 1.14 ~m. Fields chosen are representative of three independent 
experiments. 
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argues against FP producing these effects through 
chaotropic, 'detergent-like' actions. 
4. Discussion 
In this study, we show for the first time that the 
synthetic amino-terminal peptide of HIV-1 gp41 (FP) pro- 
motes fusion of a biological membrane. Specifically, FP 
triggered lipid mixing of resealed erythrocyte ghosts, and 
also caused multicellular aggregates. These results should 
be compared with previous model liposome studies using 
fusion peptides derived from the amino-terminal peptide of 
HIV gp41 [19-21]. In early work with the synthetic HIV-I 
fusion peptide Rafalski et al. [19] noted that the 23-residue 
gp41 sequence 519-541 (FP) catalyzed lipid mixing in 
small unilamellar vesicles (SUV) containing negatively- 
charged phospholipids (POPG), but not neutral phospho- 
lipids (POPC). More recently, FP was reported to induce 
lipid-mixing between the large unilamellar vesicles (LUV) 
of negatively-charged POPG, but only if Ca 2+ or Mg 2+ 
were first added to the lipid [20]; Nieva et al. [20] sug- 
gested that the lipid-mixing activity of FP with SUV of 
POPG noted by Rafalski et al. [19] may be due to the 
inherent strain in the packing of bilayer lipids in such 
small vesicles. In the absence of divalent cations, Martin et 
al. [21 ] observed that the 16-residue gp41 peptide 519-534 
induced lipid intermixing of LUV containing phosphatidyl- 
ethanolamine. Similarly, FP induced fusion of LUV con- 
taining DOPC/DOPE/cholesterol (1:1:1) in a buffer lack- 
ing divalent cations [20]. Our results showing that FP 
caused lipid-mixing between resealed erythrocyte ghosts in 
the absence of divalent cations corresponds most closely 
with the above LUV-containing phosphatidylethanolamine 
findings [20,21], since red cell membranes also have a low 
membrane curvature and contain substantial amounts of 
phosphatidyl ethanolamine [8]. 
Here, we also report that FP induces aggregation for 
human red cells suspended in buffers lacking divalent 
cations, as indicated by Coulter counter sizing studies and 
Scanning Electron Microscopy (SEM) (Figs. 6 and 7). 
Previously, Rafalski et al. [19] showed that FP caused 
aggregation of acidic (POPG) and neutral (POPC) SUV 
liposomes in the absence of divalent cations. On the other 
hand, FP did not aggregate negatively-charged POPG LUV, 
unless Ca 2+ or  Mg 2+ was first added to the buffer [20]. 
However, Nieva et al. [20] observed that FP could induce 
aggregation of LUV containing DOPC/DOPE/cholesterol 
(1:1:1) in a buffer without divalent cations, consistent with 
our results that FP aggregated red cells. 
The leakage of resealed ghosts induced by FP supports 
previous studies indicating that this viral peptide is lytic. 
The dose-response curve noted here for FP-induced leak- 
age of resealed ghosts (Fig. 3) is similar to that previously 
reported for FP-induced hemolysis [23]. However, FP-in- 
duced leakage is a much more rapid process than FP-medi- 
ated hemolysis (Fig. 3 and Mobley et al. [23]); this sug- 
gests that FP may lyse intact cells and resealed ghosts 
through distinct mechanisms. Also. it should be pointed 
out that the rapid FP-induced leakage of resealed ghosts 
(Fig. 3) is analogous to the FP-induced burst of leakage 
noted for SUV [19] or LUV [20] containing acidic lipo- 
somes (POPG) at early time poim:s (approx. 10 s), for 
resealed ghosts and vesicles each suspended in buffers 
without divalent cations. 
The actions of synthetic FP on red cell membranes 
reported here are broadly supportive of the hypothesis ( ee 
Introduction) that the amino terminus of gp41 plays a 
critical role in HIV fusion and cytolytic processes. Experi- 
ments using synthetic peptides assume that relatively short 
continuous egments (i.e., 'cassettes') exert similar func- 
tions, independent of whether these domains exist as iso- 
lated peptides or are in the intact virus [30-32]. For 
example, the HIV-L peptide at the C-terminus of HIV 
gp41 is an extremely potent cytolytic agent [31], and may 
be involved in the reduced CD4 + lymphocyte l vels seen 
in AIDS. That such a 'cassette' model may be generally 
applicable is suggested by studies showing that the fusion 
activity of the recombinant HIV Net=27 protein is retained 
by a synthetic peptide (21 residues) representing the N- 
terminal domain [33]. The clear advantage of using syn- 
thetic peptides in evaluating 'casselte' functions for HIV 
envelope proteins is that contributions from other viral 
domains are eliminated. Such a reductionist approach is 
useful in assessing the role of the N-terminal gp41 domain 
in HIV-fusion, given the likely participation of other gp41 
and gpl20 epitopes [14,17,18]. On the other hand, the 
disadvantage of synthetic peptides is that there is no ab 
initio guarantee that the conformatic.n of the isolated pep- 
tide will be functionally relevant o1" replicate that of the 
peptide in the virus. Nevertheless, Jiang et al. [34] reported 
that rabbit antisera raised to an irnmunoconjugate of a 
N-terminal gp41 peptide (residues 518-542) inhibited 
HIV-1 replication and cell fusion in vitro. This suggests 
that the synthetic N-terminal gp41 peptide assumes a 
functionally-relevant conformation. 
A critical test of the relevance of the above FP-red cell 
system in understanding HIV fusion/cytolysis comes from 
site-directed mutagenesis studies. Since replacement of 
hydrophobic amino acids with pol~Lr esidues in the N- 
terminal domain reduced HIV infectivity and syncytia 
formation in earlier mutagenic experiments [11-14], it 
would be important to learn if these substitutions similarly 
inhibit synthetic peptide-induced red cell fusion and cytol- 
ysis. Accordingly, we synthesized a FP analog (FP526L/R) 
in which Leu at position 526 was replaced with a polar 
Arg. The FP526L/R analog was chosen because an earlier 
mutagenic study, using CD4 + HeLa cells transfected with 
HIV ent ,  glycoprotein expression vectors, indicated that 
this substitution blocked syncytium formation; however, 
this replacement had no effect on gpl60 processing, pl20 
secretion and CD4 binding [12]. Our finding that 
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FP526L/R has no fusogenic (Figs. 1 and 6) or lytic (Fig. 
3) effects not only indicates that the strongly-conserved 
N-terminal gp41 domain is involved in HIV-fusion pro- 
cesses, but also confirms that addition of synthetic FP (and 
FP analogs) to red cells is a useful model for examining 
these activities. 
Our proposal that the fusogenic and/or cytolytic ac- 
tions of HIV- 1 gp41 are retained by the N-terminal peptide 
(FP) is analogous to that put forward for fusion peptides of 
related viruses. For example, Schlegel and Wade [35] 
reported that the synthetic aminoterminal peptide (i.e., 50 
/zM KFT25; 25 residues) of the G protein of vesicular 
stomatitis virus (VSV) shows both hemolytic and hemag- 
glutination activities; the fusion and lytic properties of 
KFT25 parallel those of the G protein from which the 
peptide is derived. Similarly, Wharton et al. [36] reported 
that the fusion and lytic properties of the influenza virus 
haemagglutinin (HA) were mimicked by the amino-termi- 
nal peptide (23 residues) derived from the HA 2 subunit. 
Last, Crane et al. [37] observed that the hydrophobic 
amino terminal peptide (24 residues) derived from the 
envelope protein of visna virus caused syncytia formation 
of goat cells. Antibodies to this peptide inhibited either 
visna viral-induced cell fusion or peptide-mediated fusion 
of goat cells. Since the envelope glycoprotein has previ- 
ously been shown to mediate visna virus fusion, the sim- 
plest explanation of these data is that the N-terminal 
domain retains the fusogenic activity of the whole enve- 
lope protein. 
Our studies showing that FP fuses red cell membranes 
suggest mechanisms for not only HIV fusion with CD4 ÷ 
cells but also the syncytia formation of HIV-infected CD4 ÷ 
cells. Earlier, a 'dual-receptor' model has been proposed 
for the participation of HIV infection of cells and syncytia 
produced by infected cells. The initial binding of HIV to 
target membranes occurs principally between viral gpl20 
(glycoprotein 120000) and the CD4 glycoprotein on the 
host-cell surface [38]. Early experiments indicated that, 
after this highly specific CD4-gpl20 binding (K D approx. 
10 -9 M), gpl20 may break its non-covalent interactions 
with gp41 and be shed from the viral envelope [39,40]. 
The dissociation of gpl20 may lead to exposure of previ- 
ously cryptic gp41 sites [39,40] such as an activated N- 
terminal gp41 peptide, which in turn may attack the host 
cell surface [10]. More recent work indicates that gp 120 
shedding may not be integral to the fusion cascade [41,42], 
and that a gpl20 epitope may participate with the N-termi- 
nal gp41 domain in HIV fusion [14]. Our prior structural 
studies [6] indicated that FP binds with relatively low 
specificity to either lipid or protein sites, or both. The 
envelope gp41, along with a possible contribution from 
gpl20, could act as a 'bridge,' linking the target cell 
surface bilayer (through the N-terminal peptide of gp41) 
with the HIV envelope bilayer (through the embedded 
gp41 transmembrane sequences) [8]. If the fusogenic activ- 
ity of synthetic FP reported here were retained by the 
corresponding peptide in HIV, then it would be anticipated 
that the N-terminal domain of gp41 could participate in the 
fusion of the viral envelope with target cell membranes. 
This 'dual-receptor' model is readily modified to account 
for how HIV-infected cells, which express gpl20 and gp41 
on the cell surface, fuse with uninfected CD4-bearing cells 
to form multicell syncytia. 
The results demonstrating FP fusion activity may also 
account for HIV interactions with, and infection of, cells 
which do not bear the CD4 receptor. Larsen et al. [43] 
recently reported that HIV-1 fuses with human erythrocyte 
ghosts (i.e., non-CD4 bearing cells). Exposed N-terminal 
gp41 peptides on HIV-I may bind to human red cell 
membrane proteins and lipids, thereby inducing fusion of 
opposing viral and red cell membranes. This fusion pro- 
cess may be somewhat analogous to that observed with 
synthetic N-terminal gp41 peptides and red cells. A rela- 
tively non-specific interaction between FP and target mem- 
branes may also explain how HIV infects cells (e.g., 
fibroblasts and glial cells and apical surfaces of colonic 
epithelial cells) which do not have CD4 receptors [44-46]. 
Without the targeting of the highly-specific CD4-gpl20 
interaction, however, HIV fusion with non-CD4 bearing 
cells would be expected to be only a minor pathway for 
viral infection. 
Although FP-mediated red cell aggregation (Figs. 6 and 
7) appears similar to the multicell syncytia observed in 
HIV-infected CD4 ÷ cell cultures [47], the precise mecha- 
nisms for these fusion processes must be different. For 
fusion of HIV-infected cells with uninfected cells, the 
above 'dual-receptor' model argues that host and target 
cell membranes are fused via the entire gp41 transmem- 
brane protein. However, only the 23-residue amino termi- 
nal peptide of HIV-I gp41 participates in the FP-induced 
red cell aggregation reported here. Also, it should be noted 
that FP-induced red cell aggregates (Fig. 7) are more 
strongly distorted and elongated than the multicell syncytia 
observed in HIV-infected CD4+-cell cultures [47]. 
It is important o determine the underlying physical 
mechanisms by which the N-terminal gp41 peptide induces 
red cell fusion, aggregation and lysis. Earlier structural 
studies indicated that nitroxide spin-labeled FP readily 
inserts into red cell membranes, and is capable of binding 
to endogenous lipids or proteins, or both [6]. At low 
FP/red cell lipid ratios (approx. 1:1400), FP assumes a 
monomeric, c~-helical conformation for residues 519-536 
and is oriented so that the amino terminus (Ala-519) is 
buried in the interior of the membrane bilayer and the 
C-terminal region (Met-537) is in the aqueous environ- 
ment. At high FP/lipid ratios (approx. 1:200), FP is 
aggregated into multimeric peptides and adopts both /3- 
strand and c~-helical conformations. These FP aggregates 
may be related to the filamentous tructures een in an 
electron microscopic study of the HIV-I N-terminal gp41 
peptide in aqueous medium [48]. Since FP aggregates 
occur at the same doses that trigger hemolysis [6,7,23], 
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leakage (Fig. 3), fusion (Figs. I and 2) and aggregation 
(Figs. 6 and 7), membrane aggregates of FP may be 
involved in these processes. For example, FP-induced lytic 
events may be triggered by the formation of peptide 
'pores' that allow ion flux or the creation of non-lamellar 
lipid [49]. Conceivably, FP aggregates may act to 'tether' 
adjacent red cells, thereby facilitating both lipid-mixing 
and multicell formation. It will be of considerable interest 
in future studies to determine whether the N-terminal gp41 
peptide interacts similarly with CD4-bearing cells. 
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